AstraZeneca reported an increase in second-quarter revenue, driven by income from licensing deals, though profit continued to fall as the company plowed heavy investment into new drugs it hopes will replace its old blockbusters.
from WSJ.com: US Business http://ift.tt/1DcvfOY
via IFTTT
No comments:
Post a Comment